Eylea 40mg Injection is used in adults for:

• Neovascular (wet) age-related macular degeneration (wet AMD)

• Visual impairment due to macular oedema secondary to retinal vein occlusion, including branch RVO and central RVO

• Diabetic macular oedema (DME)

• Myopic choroidal neovascularisation (myopic CNV)

The specific treatment schedule depends on the condition being treated and the response to therapy.

Eylea contains Aflibercept, a recombinant fusion protein that binds to VEGF. VEGF can promote abnormal blood vessel growth and increase leakage from blood vessels in the retina.

By binding to VEGF, Aflibercept prevents VEGF from activating its receptors. This reduces abnormal blood vessel formation and vascular leakage, helping control retinal swelling and other changes that can impair vision.

Tell your ophthalmologist about all medicines, supplements and other treatments you are receiving.

• Other anti-VEGF treatments: Tell your doctor if you are receiving another medicine that acts on VEGF.

• Other eye treatments: Inform your doctor about any other medicines or injections being used in or around the eye.

• Verteporfin photodynamic therapy: The safety of using Eylea together with verteporfin photodynamic therapy has not been established.

No specific interaction studies have been conducted with Eylea.

• Store Eylea 40mg Injection in a refrigerator between 2°C and 8°C.

• Do not freeze.

• Keep the injection in its original package to protect it from light.

• Keep out of the reach of children.

• The injection should be inspected before administration and should not be used if it appears cloudy, contains particles or has changed colour.

Eylea 40mg Injection is administered only by intravitreal injection by a qualified healthcare professional experienced in administering injections into the eye. It should not be self-administered.

Although the vial contains 40 mg/mL of Aflibercept, the recommended adult dose is generally 2 mg, equivalent to 0.05 mL per injection. The dose and frequency depend on the condition being treated.

For wet AMD, treatment generally begins with one injection each month for three consecutive doses, followed by treatment at longer intervals according to the patient's response.

For diabetic macular oedema, treatment generally begins with one injection each month for five consecutive doses, followed by injections every two months. For retinal vein occlusion, treatment is generally given monthly initially. Myopic choroidal neovascularisation is generally treated with a single 2 mg injection, with additional treatment if required based on disease activity.

Your ophthalmologist will determine the appropriate treatment schedule based on your eye examination and response to treatment.

Eylea can cause side effects, although not everyone experiences them. Some side effects are related to the injection procedure rather than the medicine itself.

Common side effects

• Conjunctival haemorrhage

• Eye pain

• Increased eye pressure

• Cataract

• Vitreous floaters

• Vitreous detachment

• Blurred or disturbed vision

• Eye redness or irritation

The most frequently reported adverse reactions include conjunctival haemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters and increased intraocular pressure.

Serious side effects

Seek immediate medical attention if you develop:

• Endophthalmitis, a serious infection inside the eye

• Severe eye pain or worsening redness

• Sudden deterioration or loss of vision

• Retinal detachment or retinal tear

• Severe inflammation inside the eye

• Significant increase in eye pressure

• Severe allergic reaction

• Arterial thromboembolic events such as stroke or heart attack

Serious ocular reactions related to the intravitreal injection procedure are uncommon but can include endophthalmitis, retinal detachment, vitreous haemorrhage, cataract and increased intraocular pressure.

• Eylea should only be administered by a qualified healthcare professional experienced in intravitreal injections.

• Attend all scheduled eye examinations so your ophthalmologist can monitor your response to treatment.

• Tell your doctor if you have had a stroke, transient ischaemic attack or heart attack, or have other risk factors for arterial thromboembolic events.

• Inform your doctor if you have an eye infection or inflammation before receiving an injection.

• Seek immediate medical attention if you develop severe eye pain, worsening redness, increased sensitivity to light or sudden changes in vision.

• Do not rub your eye after the injection unless specifically advised by your doctor.

• Maintain good control of conditions such as diabetes and high blood pressure as advised by your healthcare team.

• Do not stop or delay scheduled injections without discussing it with your ophthalmologist.

• Avoid driving until any temporary visual disturbance following the injection or eye examination has resolved.